Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Cancer Biologic Trials

New Haven, Connecticut

Cancer biologic therapy trials in New Haven, CT

37 cancer biologic therapy studies are recruiting participants at sites in New Haven as of November 18, 2026, according to ClinicalTrials.gov. Cancer Biologic Trials can help you understand your options and connect with a study team.

Call (888) 343-5902
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

New Haven at a glance

  • 37 studies are recruiting at a site in New Haven.
  • By phase: Phase 1 (5), Phase 1/2 (4), Phase 2 (10), Phase 2/3 (1), Phase 3 (17).
  • By sponsor: industry (16), university, hospital or other (12), government (9).
  • By research area: Lung Cancer (15), Breast Cancer (10), Lymphoma (10), Melanoma (1), Prostate Cancer (1).
  • Most recent update to one of these records: November 18, 2026.

Breast cancer studies recruiting in New Haven

Basic details from each study's public record (the 30 most recently updated of 37). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Yale Cancer Center ( Site 0053)
    Registry record
    NCT06393374 · updated
  2. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Yale University
    Registry record
    NCT06058377 · updated
  3. Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    Smilow Cancer Center/Yale-New Haven Hospital · Yale University
    Registry record
    NCT07578116 · updated
  4. A Study of PHST001 in Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pheast Therapeutics
    Study site
    Yale Cancer Center
    Registry record
    NCT06840886 · updated
  5. ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Yale University
    Registry record
    NCT06876714 · updated
  6. Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    BriaCell Therapeutics Corporation
    Study site
    Smilow Cancer Hospital at Yale New Haven
    Registry record
    NCT06072612 · updated
  7. Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

    • Phase 3
    • Ages 18 to 100
    • All sexes
    Sponsor
    Greenwich LifeSciences, Inc.
    Study site
    Yale Cancer Center - Smilow Cancer Hospital
    Registry record
    NCT05232916 · updated
  8. Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Yale University
    Registry record
    NCT05812807 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in New Haven, CT on ClinicalTrials.gov.

Lung cancer studies recruiting in New Haven

  1. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Yale University School of Medicine ( Site 0201)
    Registry record
    NCT06623422 · updated
  2. Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Yale University
    Registry record
    NCT06287775 · updated
  3. A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Smilow Cancer Center at Yale-New Haven ( Site 3253)
    Registry record
    NCT07513376 · updated
  4. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Yale University
    Registry record
    NCT04267848 · updated
  5. Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Yale University
    Registry record
    NCT04181060 · updated
  6. A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Johnson & Johnson Enterprise Innovation Inc.
    Study site
    Yale University
    Registry record
    NCT06667908 · updated
  7. M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    EMD Serono Research & Development Institute, Inc.
    Study site
    Yale Cancer Center
    Registry record
    NCT07166601 · updated
  8. Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    CatalYm GmbH
    Study site
    Yale Cancer Center
    Registry record
    NCT07098988 · updated
  9. Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

    • Phase 2
    • From 18 minutes
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    Yale University
    Registry record
    NCT06031688 · updated
  10. Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    Yale University
    Registry record
    NCT06116682 · updated
  11. Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    Yale University
    Registry record
    NCT06616584 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in New Haven, CT on ClinicalTrials.gov.

Prostate cancer studies recruiting in New Haven

  1. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

    • Phase 1
    • Ages 18 to 100
    • Male participants
    Sponsor
    Janux Therapeutics
    Study site
    Yale New Haven Hospital
    Registry record
    NCT05519449 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in New Haven, CT on ClinicalTrials.gov.

Melanoma studies recruiting in New Haven

  1. SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Immatics US, Inc.
    Study site
    Yale Cancer Center
    Registry record
    NCT06743126 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in New Haven, CT on ClinicalTrials.gov.

Lymphoma studies recruiting in New Haven

  1. Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Yale University
    Registry record
    NCT05272384 · updated
  2. Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

    • Phase 2
    • Up to 365 days
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Yale University
    Registry record
    NCT06317662 · updated
  3. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Yale University
    Registry record
    NCT05675410 · updated
  4. Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Yale University
    Registry record
    NCT06649812 · updated
  5. Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

    • Phase 3
    • Ages 18 to 39
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Yale University
    Registry record
    NCT03150693 · updated
  6. Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

    • Phase 3
    • Ages 60 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Yale University
    Registry record
    NCT05976763 · updated
  7. Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

    • Phase 1/2
    • From 6 months, up to 25 years
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Yale New Haven Hospital ( Site 1012)
    Registry record
    NCT06395103 · updated
  8. A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • From 366 days, up to 46 years
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Yale University
    Registry record
    NCT06124157 · updated
  9. Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

    • Phase 3
    • From 365 days, up to 25 years
    • All sexes
    Sponsor
    Children's Oncology Group
    Study site
    Yale University
    Registry record
    NCT03959085 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in New Haven, CT on ClinicalTrials.gov.

Ask about studies near New Haven

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.

Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-5902

or send a short form

How should we reach you?

Call